Research Interests

The primary focus of my laboratory is the development of radiopharmaceuticals as positron emission tomography (PET) imaging agents. These PET agents allow the quantitative assessment of biomolecular entities in vivo, aimed at diagnosis of disease, tailoring appropriate treatment (personalized medicine) and monitoring the progress of therapy based on individual patient response. In addition, these imaging agents can be used to elucidate basic biologic questions to better understand health and disease. Current imaging agent research and development are targeted at applications in psychiatry (schizophrenia, substance abuse, depression, etc.), neurology (Parkinson's and
Alzheimer's disease) and oncology (epithelial cancers).